AAP
RVMD icon

Arax Advisory Partners’s Revolution Medicines RVMD Stock Holding History

Arax Advisory Partners’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$531K Buy
2,835
+2,666
+1,578% +$389K ﹤0.01% 1602
2026
Q1 		$16.4K Sell
169
-305
-64% -$30.8K ﹤0.01% 2201
2025
Q4 		$37.8K Buy
+474
New +$31.1K ﹤0.01% 1763
2025
Q1 		– Sell
-31
Closed -$1.36K – 2992
2024
Q4 		$1.36K Hold
31
– – ﹤0.01% 2099
2024
Q3 		$1.41K Hold
31
– – ﹤0.01% 2154
2024
Q2 		$1.2K Buy
+31
New +$1.16K ﹤0.01% 2117

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Arax Advisory Partners's RVMD Position: Q2 2026 in Review

Arax Advisory Partners increased its Revolution Medicines (RVMD) stake by 1,578% in Q2 2026, buying an estimated $389K and bringing the position to 2,835 shares worth $531K. The position accounts for ﹤0.01% of the portfolio, ranked #1602.

Arax Advisory Partners first reported a position in RVMD in Q2 2024 and has held it in 6 quarters since. 690 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Arax Advisory Partners held 2,835 shares of Revolution Medicines worth $531K as of Q2 2026.
  • Arax Advisory Partners bought 2,666 Revolution Medicines shares in Q2 2026, an estimated $389K.
  • Revolution Medicines made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #1602 holding.
  • Arax Advisory Partners first reported a position in Revolution Medicines in Q2 2024 and has held it in 6 quarters since.
  • 690 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.